Literature DB >> 21052913

Comparison of the influence of intracameral gentamicin, gatifloxacin, and moxifloxacin on the corneal endothelium in a rabbit model.

Shinichiro Kobayakawa1, Yoshimune Hiratsuka, Yasuo Watabe, Akira Murakami, Tetsuo Tochikubo.   

Abstract

PURPOSE: To compare the effect of three intracameral antibiotics, gentamicin (GM), gatifloxacin (GFLX), and moxifloxacin (MFLX), on the rabbit corneal endothelium.
METHODS: Twenty-four eyes from 18 rabbits were used. In the GM treatment group of 12 eyes, a dose of 20 mg/ml, 2 mg/ml, 200 μg/ml, or 20 μg/ml of GM was injected into the anterior chamber. In the GFLX and MFLX treatment groups were injected into the anterior chamber of three eyes. The central corneal thickness was measured. The eyes were then enucleated for observation under scanning electron microscopy.
RESULTS: Three days after the intracameral injection, a significant difference in central corneal thickness was found between the GM 20 mg/ml group and the control group (P < 0.05), but not between any other groups. The damage rate at the endothelial cell level was 67% in the GM 20 mg/ml group, 56% in the GM 2 mg/ml group, 33% in the GM 200 μg/ml group, 22% in the GM 20 μg/ml group, 22% in the GFLX group, and 0% in the MFLX group.
CONCLUSIONS: Intracameral GFLX or MFLX was almost nontoxic to the rabbit corneal endothelium, in contrast to the toxic results of intracameral GM 20 and 2 mg/ml.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21052913     DOI: 10.1007/s10384-010-0838-5

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  27 in total

1.  ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: Preliminary report of principal results from a European multicenter study.

Authors:  Peter Barry; David V Seal; George Gettinby; Fiona Lees; Magnus Peterson; Crawford W Revie
Journal:  J Cataract Refract Surg       Date:  2006-03       Impact factor: 3.351

Review 2.  Toxic anterior segment syndrome.

Authors:  Nick Mamalis; Henry F Edelhauser; Daniel G Dawson; Jesse Chew; Russell M LeBoyer; Liliana Werner
Journal:  J Cataract Refract Surg       Date:  2006-02       Impact factor: 3.351

3.  Incidence of endophthalmitis after cataract surgery in Japan.

Authors:  Tetsuro Oshika; Hiroshi Hatano; Yasuaki Kuwayama; Yuichiro Ogura; Yuichi Ohashi; Kotaro Oki; Toshihiko Uno; Norio Usui; Fumiaki Yoshitomi
Journal:  Acta Ophthalmol Scand       Date:  2007-04-24

4.  Fourth-generation fluoroquinolone penetration into the aqueous humor in humans.

Authors:  J P McCulley; D Caudle; J D Aronowicz; W E Shine
Journal:  Ophthalmology       Date:  2006-04-17       Impact factor: 12.079

5.  Cytotoxicity of intracameral injection drugs to corneal endothelium as evaluated by corneal endothelial cell culture.

Authors:  C H Chang; C P Lin; H Z Wang
Journal:  Cornea       Date:  1995-01       Impact factor: 2.651

6.  Comparison of the effect of intracameral moxifloxacin, levofloxacin and cefazolin on rabbit corneal endothelial cells.

Authors:  Su-Young Kim; Young-Hoon Park; Young-Chun Lee
Journal:  Clin Exp Ophthalmol       Date:  2008-05       Impact factor: 4.207

Review 7.  Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin.

Authors:  Terrence P O'Brien; Steve A Arshinoff; Francis S Mah
Journal:  J Cataract Refract Surg       Date:  2007-10       Impact factor: 3.351

8.  Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors.

Authors: 
Journal:  J Cataract Refract Surg       Date:  2007-06       Impact factor: 3.351

9.  Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years.

Authors:  Michael K Jensen; Richard G Fiscella; Majid Moshirfar; Barbara Mooney
Journal:  J Cataract Refract Surg       Date:  2008-09       Impact factor: 3.351

10.  Comparison of in vitro safety profiles of vancomycin and cefuroxime on human corneal endothelial cells for intracameral use.

Authors:  Efdal Yoeruek; Martin S Spitzer; Oguzhan Saygili; Olcay Tatar; Tilo Biedermann; Erdal Yoeruek; Karl U Bartz-Schmidt; Peter Szurman
Journal:  J Cataract Refract Surg       Date:  2008-12       Impact factor: 3.351

View more
  6 in total

1.  Effect of topical 0.05% cyclosporine A on corneal endothelium in patients with dry eye disease.

Authors:  Consuelo Pérez-Rico; Francisco Germain; María Castro-Rebollo; Agustín Moreno-Salgueiro; Miguel Ángel Teus
Journal:  Int J Ophthalmol       Date:  2013-08-18       Impact factor: 1.779

2.  Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis.

Authors:  Randy C Bowen; Andrew Xingyu Zhou; Sailaja Bondalapati; Thomas W Lawyer; Karisa B Snow; Patrick R Evans; Tyler Bardsley; Mary McFarland; Matthew Kliethermes; Dallas Shi; Christina A Mamalis; Tom Greene; Christopher J Rudnisky; Balamurali Krishna Ambati
Journal:  Br J Ophthalmol       Date:  2018-01-11       Impact factor: 4.638

3.  Gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis: safety, efficacy and patient perspective.

Authors:  Clyde Schultz
Journal:  Ophthalmol Eye Dis       Date:  2012-07-11

4.  Toxic Anterior Segment Syndrome following Phacoemulsification Secondary to Overdose of Intracameral Gentamicin.

Authors:  Yaran Koban; Selim Genc; Gorkem Bilgin; Halil Huseyin Cagatay; Metin Ekinci; Melin Gecer; Zeliha Yazar
Journal:  Case Rep Med       Date:  2014-12-10

5.  Toxic anterior segment syndrome after uncomplicated cataract surgery possibly associated with intracamaral use of cefuroxime.

Authors:  Burçin Çakır; Erkan Celik; Nilgün Özkan Aksoy; Özlem Bursalı; Turgay Uçak; Erdinç Bozkurt; Gursoy Alagoz
Journal:  Clin Ophthalmol       Date:  2015-03-17

6.  Evaluation of moxifloxacin-induced cytotoxicity on human corneal endothelial cells.

Authors:  Joo-Hee Park; Martha Kim; Roy S Chuck; Choul Yong Park
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.